CMP: INR 8,610 Target Price: INR 8,262 (INR 7,928) 🗸 -4%

### 23 September 2023

### Cera Sanitaryware

### Sanitaryware

### Near-term demand tepidness, 2HFY24 to be much better

We recently interacted with the management of Cera Sanitaryware (CRS). Key takeaways: 1) Demand scenario in Q2-TD has been tepid as higher overall inflationary conditions have resulted in some temporary slackness. CRS expects demand to be much stronger in H2FY24 and has reiterated its ~20% YoY revenue growth guidance for FY24. 2) Margins to remain steady at ~16% as raw material costs remain benign. 3) Brownfield expansion of faucetware facility has commenced production from Sep'23 and will likely be a major growth driver. 4) Land acquisition for the sanitaryware facility is in final stages; will likely happen in Q3FY24. We continue to like CRS, as it could potentially be a significant beneficiary of the ongoing uptick in the housing market, and model revenue/PAT CAGR of 16.4%/22.3%, over FY23-26E with healthy return ratios (ROE of 20.2% in FY25E). We maintain our estimates and **HOLD** rating with a rolled over Dec'24E TP of INR 8,262 (earlier INR 7,928), set at unchanged 32x Dec'25E PER.

### Near-term demand sluggish

As per our interaction with CRS's management, demand for faucetware and sanitaryware has been sluggish in Q2FY24-TD as overall inflationary conditions have temporarily resulted in some slackness. Management believes the current lethargy in demand is temporary and H2FY24 will be much stronger, still guiding for ~20% revenue growth in FY24. The drivers of this demand will likely be uptick in housing market and continuous demand from home improvement market. Also, the commencement of the brownfield faucetware facility in Sep'23 will likely enable the company to see better growth due to favourable product mix. CRS management indicated that it is on track to achieve its guidance of doubling turnover in 40 months (from FY22) – aided primarily by growth in sanitaryware and faucetware segments. We have modelled revenue CAGR of 16.4% over FY23-26E. The land for the new greenfield sanitaryware plant should be finalised by Q3FY24, post which it will take ~18 months for the facility to commence production.

### Margins to remain steady at ~16%

CRS has taken no price hikes across segments in the ongoing quarter (Q2FY24) as raw material costs continue to be benign and the company does not foresee any pressure on margins. Management indicated that current margins of ~16% are sustainable going ahead too, led by operating leverage and improved product mix. We have modelled margins of ~16.3%-16.5% over FY23-26E (vs. reported average operating margin of ~15.1% over FY12-FY23).

### **Financial Summary**

Y/E March (INR mn)	FY23A	FY24E	FY25E	FY26E
Net Revenue	18,033	21,123	24,510	28,460
EBITDA	2,937	3,447	4,020	4,685
EBITDA %	16.3	16.3	16.4	16.5
Net Profit	1,911	2,571	2,951	3,494
EPS (Rs)	146.9	197.7	226.9	268.6
EPS % Chg YoY	32.7	34.6	14.8	18.4
P/E (x)	58.6	43.6	37.9	32.1
EV/EBITDA (x)	35.9	30.6	25.7	21.5
RoCE (%)	16.0	17.0	17.2	17.6
RoE (%)	17.5	20.4	20.2	20.7

#### Arun Baid

arun.baid@icicisecurities.com +91 22 6807 7235 **Sohil Kaura** sohil.kaura@icicisecurities.com

#### Market Data

Market Cap (INR)		1	12bn
Market Cap (USD)	1,350mn		
Bloomberg Code		С	RS IN
Reuters Code	CERA.BO		
52-week Range (INR)	9,782 /4,950		
Free Float (%)			45.0
ADTV-3M (mn) (USD)			2.7
Price Performance (%)	3m	6m	12m
Absolute	10.8	38.6	49.9
Relative to Sensex	4.7	14.5	13.1

ESG Disclosure	2021	2022	Change
ESG score	-	-	-
Environment	-	-	-
Social	-	-	-
Governance	-	-	-

**Note** - Score ranges from 0 - 100 with a higher score indicating higher ESG disclosures.

Source: Bloomberg, I-sec research

#### **Previous Reports**

05-08-2023:	Q1FY24 results review
26-05-2023:	Company update




### India | Equity Research | Company Update



### Valuation and view


We continue to like CRS due to its net cash balance sheet, wide distribution, strong brand and comprehensive product portfolio. These could strengthen its position to deliver high growth led by the ongoing uptick in housing market and increased demand from home improvement market. Maintain **HOLD** and await a better entry opportunity with a rolled over Dec'24E target price of INR 8,262 (earlier INR 7,928), set at unchanged 32x Dec'25E PER.

### **Exhibit 1:** Consol. revenue CAGR of 16.4% over FY23-FY26E aided by growth in sanitaryware and faucetware segments




Source: I-Sec research, Company data

### Exhibit 3: EBITDA CAGR at 16.8% over FY23-FY26E




Source: I-Sec research, Company data

# Exhibit 2: Sanitaryware dominates revenue mix with more than 50% share




Source: I-Sec research, Company data

### Exhibit 4: EBITDA margin to remain stable




Source: I-Sec research, Company data

# Exhibit 5: High A&P spends have enabled strong brand creation



Source: I-Sec research, Company data

### Exhibit 7: Retail dominates sales mix (FY23)




Source: I-Sec research, Company data

#### Adj. PAT 4000 3500 CAGR:22.3% 3.494 3000 2,951 2500 الالا 1500 الالا 1500 2,57 ,911 .440 1000 500 0 FY22 FY23 FY24E FY25E FY26E

Source: I-Sec research, Company data


## Exhibit 9: APAT CAGR likely at 22.3% over FY23-FY26E

## Exhibit 6: Dealer network grew 3.6x over FY17-FY23



Source: I-Sec research, Company data

### Exhibit 8: Strong presence in tier-3 and below markets



Source: I-Sec research, Company data

#### RoE (%) 25% 20.7% 20.4% 20.2% 20% 17.5% 15.3% 15% 10% 5% 0% FY26E FY22 FY23 FY24E FY25E

Source: I-Sec research, Company data

### Exhibit 10: RoE to remain healthy over FY24-FY26E

India | Equity Research





### Valuation

CRS is one of the major organised sanitaryware players in India. Over the years, the company has expanded its product portfolio from sanitaryware to tiles, faucets and wellness goods, becoming a one-stop bathroom solution provider. It has significant presence in tier-2 and tier-3 markets with strong brand name and wide distribution.

CRS is expected to witness revenue/EBIDTA CAGR of 16.4%/16.8%, respectively, during FY23-FY26E, with continued strong balance sheet and healthy return ratios (RoE of 20.7% in FY26E). We maintain HOLD rating on the stock with a rolled over Dec'24E target price of INR8,262 (earlier: INR7,928), set at an unchanged 32x Dec'25E P/E, in line with the historical 5-year average, 1-year forward P/E.

### Exhibit 11: 1-year forward PE band



Source: I-Sec research, Company data

### Key downside risks


- Unexpected slowdown in housing market would adversely affect business.
- Higher raw material prices may adversely affect profitability and demand.

### Key upside risks

- Sharp decline in raw material prices could result in better-than-expected profitability.
- Better than expected pickup in demand scenario.

#### Exhibit 12: Shareholding pattern % Dec'22 Mar'23 Jun'23 54.5 54.5 54.5 Promoters Institutional investors 26.9 27.8 28.5 8.9 MFs and others 9.3 9.6 Insurance 0.1 0.1 0.1 17.5 18.1 19.5 Flls 17.7 17.0 Others 18.6

### Exhibit 13: Price chart



Source: Bloomberg

Source: Bloomberg



### **Financial Summary**

### Exhibit 14: Profit & Loss

### (INR mn, year ending March)

	FY23A	FY24E	FY25E	FY26E
Net Sales	18,033	21,123	24,510	28,460
Operating Expenses	15,096	17,675	20,489	23,775
EBITDA	2,937	3,447	4,020	4,685
EBITDA Margin (%)	16.3	16.3	16.4	16.5
Depreciation & Amortization	326	379	454	509
EBIT	2,611	3,069	3,566	4,175
Interest expenditure	60	54	30	17
Other Non-operating Income	43	494	491	618
Recurring PBT	2,593	3,508	4,027	4,776
Less: Taxes	(738)	(919)	(1,055)	(1,251)
PAT	1,855	2,589	2,972	3,525
Profit / (Loss) from Associates	-	-	-	-
Less: Minority Interest	(16)	(18)	(22)	(31)
Extraordinaries (Net)	256	-	-	-
Net Income (Reported) Net Income (Adjusted)	2,094 1,911	2,571 2,571	2,951 2,951	3,494 3,494

Source Company data, I-Sec research

### Exhibit 15: Balance sheet

#### (INR mn, year ending March)

	FY23A	FY24E	FY25E	FY26E
Assets				
Inventories	3,825	4,455	5,164	5,993
Cash & cash eqv.	6,859	6,725	8,815	11,123
Sundry Debtors	1,892	2,199	2,552	2,963
Other Current Assets	596	694	806	936
Trade payables	2,069	2,433	2,823	3,278
Other Current Liabilities	1,958	2,528	2,933	3,406
Net Current Assets	9,145	9,113	11,580	14,330
Investments	31	31	31	31
Net Fixed Assets	3,308	5,129	4,735	4,446
Other Non Current Assets	256	256	256	256
Total Assets	12,739	14,528	16,603	19,063
Liabilities				
Borrowings	253	180	120	50
Other Non Current	654	686	718	750
Liabilities	054	000	/10	750
Total Liabilities	907	866	838	800
Equity Share Capital	65	65	65	65
Reserves & Surplus	11,661	13,474	15,554	18,022
Total Net Worth	11,726	13,539	15,619	18,087
Minority Interest	106	124	146	177
Total Liabilities & Net Worth	12,739	14,528	16,603	19,063

Source Company data, I-Sec research

### Exhibit 16: Quarterly trend

(INR mn, year ending March)

	Sep-22	Dec-22	Mar-23	Jun-23
Net Sales	4,159	4,578	5,325	4,289
% growth (YOY)	5.6	18.0	20.9	8.0
EBITDA	679	750	872	704
Margin %	16.3	16.4	16.4	16.4
Other Income	106	132	124	153
Extraordinaries	0	0	50	0
Adjusted Net Profit	507	564	666	563

Source Company data, I-Sec research

### **Exhibit 17: Cashflow statement**

(INR mn, year ending March)

	FY23A	FY24E	FY25E	FY26E
Operating Cashflow	724	2,916	3,102	3,656
Working Capital Changes	(1,698)	(102)	(378)	(442)
Capital Commitments	852	(2,200)	(61)	(220)
Free Cashflow	1,577	716	3,042	3,436
Other investing cashflow	50	-	-	-
Cashflow from Investing Activities	902	(2,200)	(61)	(220)
Issue of Share Capital	0	-	-	-
Inc (Dec) in Borrowings	(13)	(73)	(60)	(70)
Dividend paid	(650)	(777)	(892)	(1,057)
Others	114	0	-	-
Cash flow from Financing Activities	(549)	(850)	(952)	(1,127)
Chg. in Cash & Bank balance	1,077	(134)	2,090	2,309
Closing cash & balance	6,859	6,725	8,815	11,123

Source Company data, I-Sec research

#### Exhibit 18: Key ratios

(Year ending March)

	FY23A	FY24E	FY25E	FY26E
Per Share Data (INR)				
Reported EPS	161.0	197.7	226.9	268.6
Adjusted EPS (Diluted)	146.9	197.7	226.9	268.6
Cash EPS	172.0	226.8	261.8	307.8
Dividend per share (DPS)	50.0	59.7	68.6	81.3
Book Value per share (BV)	901.6	1,041.0	1,200.9	1,390.7
Dividend Payout (%)	34.0	30.2	30.2	30.3
Growth (%)				
Net Sales	24.8	17.1	16.0	16.1
EBITDA	26.9	17.4	16.6	16.5
EPS (INR)	32.7	34.6	14.8	18.4
Valuation Ratios (x)				
P/E	58.6	43.6	37.9	32.1
P/CEPS	50.1	38.0	32.9	28.0
P/BV	9.5	8.3	7.2	6.2
EV / EBITDA	35.9	30.6	25.7	21.5
EV / Sales	5.8	5.0	4.2	3.5
Dividend Yield (%)	0.6	0.7	0.8	0.9
Operating Ratios				
Gross Profit Margins (%)	89.4	54.3	54.3	54.3
EBITDA Margins (%)	16.3	16.3	16.4	16.5
Effective Tax Rate (%)	28.5	26.2	26.2	26.2
Net Profit Margins (%)	10.6	12.2	12.0	12.3
NWC / Total Assets (%)	13.6	12.3	12.4	12.5
Net Debt / Equity (x)	(0.6)	(0.5)	(0.6)	(0.6)
Net Debt / EBITDA (x)	(2.2)	(1.9)	(2.2)	(2.4)
Profitability Ratios				
RoCE (%) (post-tax)	16.0	17.0	17.2	17.6
RoE (%)	17.5	20.4	20.2	20.7
Cash Conversion Cycle				
(on net sales)				
Inventory Turnover Days	77	77	77	77
Receivables Days	38	38	38	38
Payables Days	42	42	42	42

Source Company data, I-Sec research



This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet\_babbar@icicisecuritiesinc.com, Rishi aarawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise) BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

#### ANALYST CERTIFICATION

I/We, Arun Baid, MBA; Sohil Kaura, M.Com (Finance); authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.



Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, **E-mail Address** : <u>complianceofficer@icicisecurities.com</u> For any queries or grievances: <u>Mr. Prabodh Avadhoot</u> Email address: <u>headservicequality@icicidirect.com</u> Contact Number: 18601231122